Monthly Archives: October 2024

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

28/10/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with masitinib

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

17/10/2024 – AB Science today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis

Revenues for the first half of 2024 and update on AB Science’s activities

10/10/2024 – AB Science today reports its revenues for the first half of 2024 and provides an update on its activities

AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million euros

09/10/2024 – AB Science announces today that it has completed the settlement and delivery of the capital increase announced on September 30, 2024